Ascidian Therapeutics
PrivateLast Round
Series A
Extension
Nov 8, 2023
Total Funding Raised
$90M
Company Overview
Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics that target the root causes of diseases by excising harmful genes and replacing them with healthy ones to restore normal protein production.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ascidian Therapeutics Comparables
Compare Ascidian Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Therapeutics | 89% | |
| AIRNA | 85% | |
| Tacit Therapeutics | 85% | |
Ascidian Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 8, 2023 | ||||
| Series A | Oct 12, 2022 |
Key People
Founding team and executive leadership
Ascidian Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A, Series A Extension |
| Pathway Bioventures | Series A |
Ascidian Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ascidian Therapeutics's valuation, stock price, and market status.